2013～2017年杭州市12家医院肺癌患者免疫增强药物应用分析  

Analysis of Immunomodulating Agents Used for Lung Cancer in 12 Hangzhou Hospitals from 2013 to 2017

作　　者：孙娇[1] 辛文秀 孔思思 陈凌亚[1] 黄萍[1] Sun Jiao;Xin Wenxiu;Kong Sisi;Chen Lingya;Huang Ping(Department of Pharmacy,Zhejiang Cancer Hospital,Hangzhou 310022,China)

机构地区：[1]浙江省肿瘤医院药剂科

出　　处：《药物流行病学杂志》2019年第7期460-463,486,共5页Chinese Journal of Pharmacoepidemiology

基　　金：浙江省医学会临床科研资金项目(编号:2016ZYC-A05)

摘　　要：目的:了解2013~2017年杭州市12家医院肺癌患者免疫增强药物的用药特点和趋势,为其合理用药提供参考。方法:抽取2013~2017年杭州市12家医院肺癌患者的全部用药数据,对其使用免疫增强药物的品规、销售金额、用药频度(DDDs)及限定日费用(DDC)进行排序,回顾性分析其用药特点。结果:2013~2017年杭州市12家医院肺癌患者免疫增强药物的用药金额逐年上升,其总金额占比也呈缓慢升高趋势。5年内销售金额最高的药物为胸腺法新,乌苯美司占据DDDs排名和序号比首位,注射用A群链球菌则高居DDC榜首。结论:杭州市12家医院肺癌患者使用免疫增强药物品种基本合理,服用方便、经济有效的免疫增强药物在临床使用中占优势。Objective: To analyze the characteristic and tendency of immunomodulating agents used by lung cancer patients and provide evidence for rational use of drugs. Methods: Retrospectively analyze drug variety,prescription amount, DDDs and DDC of immunomodulating agents used by lung cancer patients in 12 Hangzhou hospitals from 2013 to 2017. Results: The proportion of consumption sum of immunomodulating agents were slowly increased from 2013 to 2017. The top immunomodulating agents of the consumption sum was thymalfasin,ubenimex took the first place in DDDs and ranking ratio,and streptococcus A group injection topped the list in DDC. Conclusion: The utilization of immunomodulating agents varieties used by lung cancer patients was generally reasonable,and drugs that were convenient to take and costeffective were dominant in clinical use.

关 键 词：免疫增强药物 肺癌 金额 用药频度 限定日费用 序号比 药物利用 

分 类 号：R979.5[医药卫生—药品]